48 results on '"Shen, Xiaopei"'
Search Results
2. Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness.
3. RankDMG: a differentially methylated gene analysis method for three special scenarios
4. Editorial: Novel approaches and concepts of biomarker discovery for cancer
5. The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer
6. RNAPhaSep: a resource of RNAs undergoing phase separation
7. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
8. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
9. Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
10. RNAPhaSep: a resource of RNAs undergoing phase separation.
11. BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma
12. Correction: Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer
13. Decreased breast cancer-specific mortality risk in patients with a history of thyroid cancer
14. Viewing cancer genes from co-evolving gene modules
15. The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer
16. Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old
17. BRAFV600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
18. BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer
19. Reply to M. Melo et al
20. Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer
21. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment
22. A six-genotype genetic prognostic model for papillary thyroid cancer
23. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness
24. Stage II Differentiated Thyroid Cancer Is a High-Risk Disease in Patients <45/55 Years Old.
25. Response
26. REC8is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer
27. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
28. Separate enrichment analysis of pathways for up- and downregulated genes
29. Evidence That HIV-1 CRF01_AE Is Associated with Low CD4+T Cell Count and CXCR4 Co-Receptor Usage in Recently Infected Young Men Who Have Sex with Men (MSM) in Shanghai, China
30. Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers
31. An Integrated Approach to Uncover Driver Genes in Breast Cancer Methylation Genomes
32. Identifying Driver Genes of Breast Cancer by Integrated Analysis of Methylation and Expression Data in Paired Disease-Normal Samples of Patients
33. Distinct Functional Patterns of Gene Promoter Hypomethylation and Hypermethylation in Cancer Genomes
34. Reproducibility and Concordance of Differential DNA Methylation and Gene Expression in Cancer
35. Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control
36. Evaluation of cDNA Microarray Data by Multiple Clones Mapping to the Same Transcript
37. Identifying Candidate Cancer Genes Based on Their Somatic Mutations Co-Occurring with Cancer Genes in Cancer Genome Profiling
38. Single‐cell transcriptomic analysis of the senescent microenvironment in bone metastasis.
39. Response.
40. Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
41. The genetic duet of concurrent RASAL1 and PTEN alterations promotes cancer aggressiveness by cooperatively activating the PI3K-AKT pathway.
42. Genetic trio of BRAF and TERT alterations and rs2853669TT in papillary thyroid cancer aggressiveness.
43. The Genetic Duet of BRAF V600E and TERT Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer.
44. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
45. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
46. REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer.
47. Separate enrichment analysis of pathways for up- and downregulated genes.
48. Evaluation of cDNA microarray data by multiple clones mapping to the same transcript.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.